Resources

Publish Date
Public Comments
C4IP Post-Hearing Brief RE: U.S. International Trade Commission Investigation No. 332-596: COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities
Council for Innovation Promotion
Public Comments
C4IP Testimony RE: U.S. International Trade Commission Investigation No. 332-596: COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities
Council for Innovation Promotion
Letters
C4IP Letter to Senate HELP Committee RE: The Bayh-Dole Act and 28 U.S. Code § 1498
Council for Innovation Promotion
Public Comments
C4IP Comments RE: Joint USPTO-FDA Collaboration Initiatives (PTO-P-2022-0037)
Council for Innovation Promotion
Public Comments
C4IP Comments RE: Certain Light-Based Physiological Measurement Devices and Components Thereof (337-TA-1276)
Council for Innovation Promotion
Public Comments
C4IP Comments RE: Request for Comments on USPTO Initiatives To Ensure the Robustness and Reliability of Patent Rights (PTO-P-2022-0025)
Council for Innovation Promotion
External Resources
IP, Innovation, and American Universities, Bayh-Dole Coalition
Council for Innovation Promotion
Letters
C4IP Letter to Secretary Becerra RE: Xtandi March-In Petition
Council for Innovation Promotion
Letters
C4IP Letter to Senate Judiciary Committee RE: The Interagency Patent Coordination and Improvement Act of 2022
Council for Innovation Promotion
Letters
C4IP Letter to House and Senate Judiciary Committees RE: Patent Eligibility Restoration Act
Council for Innovation Promotion
External ResourcesReports
Intellectual property and the U.S. economy: Third edition
USPTO
External Resources
USIJ White Paper on Fintiv Doctrine
USIJ
Resources:

Resources:

C4IP Post-Hearing Brief RE: U.S. International Trade Commission Investigation No. 332-596: COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities,

03/29/2023

Resources:

Resources:

C4IP Testimony RE: U.S. International Trade Commission Investigation No. 332-596: COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities,

03/29/2023

Resources:

Resources:

C4IP Letter to Senate HELP Committee RE: The Bayh-Dole Act and 28 U.S. Code § 1498,

03/17/2023

Resources:

Resources:

C4IP Comments RE: Joint USPTO-FDA Collaboration Initiatives (PTO-P-2022-0037),

03/10/2023

Resources:

Resources:

C4IP Comments RE: Certain Light-Based Physiological Measurement Devices and Components Thereof (337-TA-1276),

02/23/2023

Resources:

Resources:

C4IP Comments RE: Request for Comments on USPTO Initiatives To Ensure the Robustness and Reliability of Patent Rights (PTO-P-2022-0025),

01/31/2023

Resources:

Resources:

IP, Innovation, and American Universities, Bayh-Dole Coalition,

01/15/2023

Resources:

Resources:

C4IP Letter to Secretary Becerra RE: Xtandi March-In Petition,

12/15/2022

Resources:

Resources:

C4IP Letter to Senate Judiciary Committee RE: The Interagency Patent Coordination and Improvement Act of 2022,

12/13/2022

Resources:

Resources:

C4IP Letter to House and Senate Judiciary Committees RE: Patent Eligibility Restoration Act,

10/13/2022

Resources:

Resources:

Intellectual property and the U.S. economy: Third edition,

03/30/2022

Resources:

Resources:

USIJ White Paper on Fintiv Doctrine,

11/29/2021

Scroll to Top